INGN Company Profile and Key Details

INGN has shown mixed momentum, losing 0.0% over the past week and -25.81% over the past quarter, though year-to-date performance is down -7.59%. Short-term trend indicators are bullishly aligned (SMA20 10.12%, SMA50 2.59%, SMA200 -8.8%). The stock’s 14-day RSI is 61.31 (firm momentum), while the ATR of 0.32 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.06% below its high and over 20.6% above its low. Average 10-day trading volume of 347.44 thousand shares is in line with the 3-month average of 328.44 thousand, indicating normal recent market interest.

Inogen, Inc. has 27.04 million shares outstanding. The public float is 23.96 million shares, elevated short interest at 3.33% of float. This equals 892.30 thousand shares. The short ratio is 5.11 days. Institutional investors hold 87.08% of the float. Insiders own 11.97%. Novo Holdings A/S holds 2.08 million shares, Smith Kevin Raymond Merrill has 70.27 thousand shares and Taylor Brenton has 56.86 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.77 thousand shares across 1 transactions.

Inogen, Inc. generated EPS of -$0.86 over the past year. Five-year average earnings growth is -26.38%. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.28. Next year's EPS is expected at $33.08. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $12.00. The high target offers 118.75% upside. The low target suggests 87.5% downside. The mean target is $13.00. This offers 103.12% upside. Inogen, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 07, 2026, missed forecasts by 25.0%. The prior quarter beat by -27.78%. Over the last six quarters, Apple has recorded several small beats. These include -26.79% in February 25, 2025.

Inogen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$6.86. This means the shares are trading below this model’s fair value.

Inogen, Inc. (NASDAQ:INGN) closed at $6.47 USD, gaining $0.07 (1.09%) from the previous close of $6.40. The stock is currently mid-range between its 52-week high and low $5.34 and $9.13. With a market capitalization of about $175.17 million, Inogen, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.59). Key stats such as the average daily volume over the past year has been around 324.53 thousand shares, volume is running light vs its 52-week average. Headquartered in Goleta, CA, Inogen, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Kevin R. Smith, the company employs approximately 766 people and listed since February 14, 2014. Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment.

Inogen, Inc. trades at a P/E ratio of -7.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.49 and a price-to-book ratio of 0.96 suggesting the stock is closer to book value. The P/FCF stands at -16.93, also below market averages.

Our AI price prediction model suggests that Inogen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.53%, with price expected at $6.11 by June 26, 2026, within a range of $5.88 to $6.32 3-Month Outlook: Projected rise of 2.66%, reaching $6.57 by September 10, 2026, with a range of $6.07 to $7.00. 1-Year Outlook: Projected gain of 111.25%, with price at $13.52 by June 11, 2027, within a range of $5.75 to $17.35.

Inogen, Inc. (NASDAQ:INGN) shares are flat -7.59% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Inogen, Inc. trading at a premium to the broader market with a P/E of -7.02. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $94.59, suggesting 1377.97% upside. Our AI forecast model points to short-term weakness (-4.53% over two weeks), a medium-term rise (2.66% over three months), and a longer-term gain (111.25% over one year), with expected trading ranges indicating moderate volatility.